Found 4 matching trials
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) PHASE1 The purpose of this study is to determine whether the combination of a neoa...
Show More Location
Johns Hopkins SKCCC
Learn More & Join Trial
DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma PHASE1 The primary objective of the trial is the safety and tolerability of admini...
Show More Location
Sidney Kimmel Comprehensive Cancer Center
Learn More & Join Trial
FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition PHASE1 The aim of this clinical trial is to evaluate the immunogenicity along with...
Show More Location
University Hospital Tuebingen
Learn More & Join Trial
Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA PHASE1 The aim of this clinical trial is to evaluate the immunogenicity along with...
Show More Location
University Hospital Tuebingen
Learn More & Join Trial